At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 246 enrolled
Drug / intervention
Selegiline Transdermal Patch +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System (STS) as an Aid for Smoking Cessation.
In Brief
A Phase 2 clinical trial evaluating Selegiline Transdermal Patch, Placebo, and 1 other intervention for Nicotine Dependence. Completed, enrolled 246 participants across 4 sites.
Detailed Summary
The purpose of this study is designed to examine the effects of Selegiline Transdermal System and behavioral intervention in smoking cessation as compared to behavioral intervention alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence
CountriesUnited States
CollaboratorsVA Office of Research and Development
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartJun 2007
Primary CompletionAug 2008
Study CompletionJan 2009
TodayJul 2026
First PostedFeb 23, 2007
Enrollment StartJun 1, 2007
Primary CompletionAug 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.4 years ago
Interventions
Selegiline Transdermal Patchdrug
Selegiline cm(2) via transdermal system
Placebodrug
Matching placebo via transdermal system
Smoking Cessation Counselingbehavioral
Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks